Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7Source: DataRank Database

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors is a research paper published in Nature (2024). On theSindex it has a DataRank of 0.769. It has been cited 168 times.

N/A

0.769DataRank · unranked

Scored on demand from live citation data

Open Access168 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (20 grants)Impact (FWCI 29.98)OA: hybridTopics (122)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.769

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (100)

Haniel A. Araújo ORCID,Minh Truong ORCID,Yu Qian ORCID,Xin Sun ORCID,Ana Galán‐Cobo ORCID

Live enrichment

PubMed:39385035 OpenAlex:https://openalex.org/W4403243250

National Institutes of Health

Grant: 1S10OD024977-01

NovaSeq6000

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

National Institutes of Health

Grant: 5R01CA262469-04

Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer

National Institutes of Health

Grant: 3P30CA016058-15S1

CORE--HORMONE RECEPTOR LABORATORY

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 5R01CA205150-02

Therapeutic approaches for LKB1-deficient non-small cell lung cancer

National Institutes of Health

Grant: 3P50CA070907-02S1

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCER

National Institutes of Health

Grant: 1R01CA279452-01A1

Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor

NCI NIH HHS

Grant: R01 CA262469

NCI NIH HHS

Grant: P30 CA016672

NCATS NIH HHS

Grant: UL1 TR001863

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: P30 CA016042

NIH HHS

Grant: S10 OD024977

NCI NIH HHS

Grant: R01 CA279452

NCI NIH HHS

Grant: R01 CA205150

NCI NIH HHS

Grant: T32 CA009172

NCI NIH HHS

Grant: R01 CA276917

NCI NIH HHS

Grant: P30 CA016058

NCI NIH HHS

Grant: P50 CA070907

FWCI

29.98

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1038/s41586-024-07943-7

publisherhttps://doi.org/10.1038/s41586-024-07943-7

publisherhttps://www.nature.com/articles/s41586-024-07943-7.pdf

publisherhttps://www.nature.com/articles/s41586-024-07943-7

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39385035

Fields of Study

Cancer Immunotherapy and BiomarkersMelanoma and MAPK PathwaysColorectal Cancer Treatments and Studies0302 clinical medicine03 medical and health sciencesAnimalsFemaleHumansMaleMiceAMP-Activated Protein Kinase KinasesAntibodies, MonoclonalB7-H1 AntigenCarcinoma, Non-Small-Cell LungClinical Trials, Phase III as TopicCTLA-4 AntigenDrug Resistance, NeoplasmImmune Checkpoint InhibitorsKelch-Like ECH-Associated Protein 1Lung NeoplasmsMutationNitric Oxide Synthase Type IIT-LymphocytesTumor MicroenvironmentTumor Suppressor ProteinsGenes, Tumor SuppressorAntibodies, Monoclonal, Humanized

MeSH Terms

Kelch-Like ECH-Associated Protein 1Immune Checkpoint InhibitorsAMP-Activated Protein Kinase KinasesAnimalsAntibodies, MonoclonalCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMutationT-LymphocytesGenes, Tumor SuppressorClinical Trials, Phase III as TopicProtein Serine-Threonine KinasesDrug Resistance, NeoplasmTumor Suppressor ProteinsMiceNitric Oxide Synthase Type IITumor MicroenvironmentB7-H1 AntigenCTLA-4 AntigenAntibodies, Monoclonal, Humanized

Keywords

BlockadeCancer researchMedicinePharmacologyChemistryInternal medicineReceptorMaleLung NeoplasmsGeneral Science & Technology (science-metrix)T-LymphocytesMonoclonal (mesh)Drug ResistanceNitric Oxide Synthase Type IIPhase III as Topic (mesh)Lung (rcdc)B7-H1 AntigenMiceAMP-Activated Protein Kinase KinasesCarcinoma, Non-Small-Cell LungMonoclonalTumor MicroenvironmentAnimals (mesh)T-Lymphocytes (mesh)CTLA-4 AntigenNon-Small-Cell Lung32 Biomedical and Clinical Sciences (for-2020)Male (mesh)Immune Checkpoint InhibitorsCancer (rcdc)Humans (mesh)Kelch-Like ECH-Associated Protein 1/metabolism; Kelch-Like ECH-Associated Protein 1/genetics; Humans; Animals; Mice; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/genetics; Carcinoma, Non-Small-Cell Lung/pathology; Carcinoma, Non-Small-Cell Lung/immunology; Protein Serine-Threonine Kinases/metabolism; Protein Serine-Threonine Kinases/antagonists & inhibitors; Protein Serine-Threonine Kinases/genetics; Immune Checkpoint Inhibitors/pharmacology; Immune Checkpoint Inhibitors/therapeutic use; Drug Resistance, Neoplasm/drug effects; AMP-Activated Protein Kinase Kinases; Lung Neoplasms/drug therapy; Lung Neoplasms/genetics; Lung Neoplasms/immunology; Lung Neoplasms/pathology; CTLA-4 Antigen/antagonists & inhibitors; CTLA-4 Antigen/metabolism; B7-H1 Antigen/metabolism; B7-H1 Antigen/antagonists & inhibitors; Female; Male; Mutation; Antibodies, MonoclonalKelch-Like ECH-Associated Protein 1Immune Checkpoint Inhibitors (mesh)Mutation (mesh)Mice (mesh)Tumor Suppressor (mesh)Antibodies, MonoclonalNitric Oxide Synthase Type II (mesh)Phase III as TopicLung Cancer (rcdc)FemaleNon-Small-Cell Lung (mesh)Neoplasm (mesh)Tumor SuppressorTumor Suppressor Proteins (mesh)610AntibodiesArticleCTLA-4 Antigen (mesh)5.1 Pharmaceuticals (hrcs-rac)AnimalsHumansClinical Trials3204 Immunology (for-2020)AMP-Activated Protein Kinase Kinases (mesh)Lung Neoplasms (mesh)Kelch-Like ECH-Associated Protein 1 (mesh)Tumor Suppressor ProteinsCarcinomaImmunotherapy (rcdc)2.1 Biological and endogenous factors (hrcs-rac)Cancer (hrcs-hc)B7-H1 Antigen (mesh)Tumor Microenvironment (mesh)3211 Oncology and Carcinogenesis (for-2020)GenesClinical Trials, Phase III as TopicDrug Resistance, NeoplasmFemale (mesh)MutationNeoplasm